Eli Lilly has entered a global licensing and research collaboration with Lila Biologics to develop AI-designed radioligands for imaging and treatment of solid tumors. Using Lila's machine learning and protein design platforms, the partnership aims to discover novel radiotherapeutic agents with high tumor specificity and favorable safety profiles. Radioligand therapy attaches radioactive isotopes to cancer-targeting molecules for selective tumor destruction. The collaboration will advance IND-enabling studies, clinical development, and potential commercialization, highlighting AI's growing role in precision oncology drug discovery.